Clinical Trials Browser

Phase 1 × Hodgkin Disease × umbralisib × Clear all

NCT02164006 2019-10-02

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Phase 1 Completed

Hodgkin Disease